PL2762143T3 - Kompozycje obejmujące 15-HEPE i sposoby ich stosowania - Google Patents

Kompozycje obejmujące 15-HEPE i sposoby ich stosowania

Info

Publication number
PL2762143T3
PL2762143T3 PL13176516T PL13176516T PL2762143T3 PL 2762143 T3 PL2762143 T3 PL 2762143T3 PL 13176516 T PL13176516 T PL 13176516T PL 13176516 T PL13176516 T PL 13176516T PL 2762143 T3 PL2762143 T3 PL 2762143T3
Authority
PL
Poland
Prior art keywords
hepe
compositions
methods
same
Prior art date
Application number
PL13176516T
Other languages
English (en)
Polish (pl)
Inventor
Jonathan Rowe
Kevin Duffy
John Climax
Original Assignee
Dignity Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dignity Sciences Ltd filed Critical Dignity Sciences Ltd
Publication of PL2762143T3 publication Critical patent/PL2762143T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
PL13176516T 2013-01-30 2013-07-15 Kompozycje obejmujące 15-HEPE i sposoby ich stosowania PL2762143T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1301626.6A GB201301626D0 (en) 2013-01-30 2013-01-30 Composition comprising 15-OHEPA and methods of using the same
EP13176516.6A EP2762143B1 (en) 2013-01-30 2013-07-15 Compositions comprising 15-HEPE and methods of using the same

Publications (1)

Publication Number Publication Date
PL2762143T3 true PL2762143T3 (pl) 2016-06-30

Family

ID=47891001

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13176516T PL2762143T3 (pl) 2013-01-30 2013-07-15 Kompozycje obejmujące 15-HEPE i sposoby ich stosowania

Country Status (27)

Country Link
US (6) US20150224076A1 (https=)
EP (2) EP2762143B1 (https=)
JP (2) JP6363104B2 (https=)
KR (6) KR20250105691A (https=)
CN (2) CN111214464A (https=)
AU (2) AU2014211628B2 (https=)
BR (1) BR112015018270A2 (https=)
CA (1) CA2897343C (https=)
CY (1) CY1117209T1 (https=)
DK (1) DK2762143T3 (https=)
ES (2) ES2759448T3 (https=)
GB (1) GB201301626D0 (https=)
HR (1) HRP20160203T1 (https=)
HU (1) HUE026901T2 (https=)
IL (3) IL239893A (https=)
MX (2) MX364646B (https=)
NZ (1) NZ709803A (https=)
PH (1) PH12015501582B1 (https=)
PL (1) PL2762143T3 (https=)
PT (1) PT2762143E (https=)
RS (1) RS54584B1 (https=)
RU (2) RU2671208C2 (https=)
SG (2) SG11201505457PA (https=)
SI (1) SI2762143T1 (https=)
SM (1) SMT201600069B (https=)
WO (1) WO2014118097A1 (https=)
ZA (2) ZA201505018B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
EP3068757B1 (en) 2013-11-15 2019-02-27 DS Biopharma Limited Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid
SG10202000496XA (en) * 2014-01-10 2020-03-30 Afimmune Ltd Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
EP3247348A1 (en) * 2015-01-16 2017-11-29 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
BR112017023164A2 (en) 2015-04-28 2018-07-24 Pronova Biopharma Norge As and method of preventing and / or treating non-alcoholic steatohepatitis in an individual in need thereof
CN117402059A (zh) * 2015-05-13 2024-01-16 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
JP2018520197A (ja) * 2015-07-21 2018-07-26 アフィミューン リミテッド 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物
KR20180094516A (ko) * 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
HRP20241643T1 (hr) 2017-12-06 2025-02-14 Basf As Derivati masnih kiselina za liječenje nealkoholnog steatohepatitisa
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN115215725A (zh) * 2021-04-15 2022-10-21 宋晓瑜 一种制备乙酸薰衣草酯及薰衣草醇的方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JPH09505562A (ja) 1993-10-01 1997-06-03 アール．ピー．シェーラー コーポレイション 香料を小分けして提供する方法および組成物
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
JP4932116B2 (ja) 2000-02-16 2012-05-16 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド アスピリン誘発脂質メディエータ
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
SK14502003A3 (en) 2001-05-30 2004-10-05 Laxdale Ltd Coenzyme Q and eicosapentaenoic acid
CN1250230C (zh) * 2001-09-30 2006-04-12 中国药品生物制品检定所 海狗油作为制备治脂肪肝药的应用
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
US20070105954A1 (en) 2003-12-31 2007-05-10 Ingennus Limited Formulation containing a carboxylic acid or an ester thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
BRPI0512864B8 (pt) 2004-07-01 2021-05-25 Johnson & Johnson Vision Care composição oftálmica, uso de pelo menos um ácido graxo ômega-6 e pelo menos um ácido graxo ômega-3 e método para preparar a referida composição
EP1973536A2 (en) * 2006-01-05 2008-10-01 Reliant Pharmaceuticals, Inc. Treatment of fatty liver
BRPI0715402A2 (pt) 2006-08-08 2013-11-26 Lipomics Technologies Inc Marcadores de doença hepática gordurosa não alcoólica (nafld) e esteatohepatite não alcoólica (nash) e métodos de uso dos mesmos
WO2008126363A1 (ja) * 2007-03-30 2008-10-23 Kowa Company, Ltd. 脂肪肝又は非アルコール性脂肪性肝炎の予防及び／又は治療のための医薬
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2009154230A1 (ja) * 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
EP2415748A4 (en) * 2009-02-20 2013-08-07 Univ Tokyo NEW INFLAMMATORY COMPOUNDS
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
JP5909183B2 (ja) * 2010-08-19 2016-04-26 国立大学法人 東京大学 オメガ３系脂肪酸由来の新規抗炎症性代謝物
US20130310422A1 (en) 2010-09-01 2013-11-21 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
WO2012135032A2 (en) 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
SG11201401629XA (en) 2011-10-19 2014-05-29 Dignity Sciences Ltd Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
SG11201402653QA (en) 2011-11-29 2014-06-27 Dignity Sciences Ltd Compositions comprising 20-carbon fatty acids and methods of making and using same
UA114615C2 (uk) 2012-01-06 2017-07-10 Омтера Фармасьютікалз, Інк. Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
DK2858496T3 (da) * 2012-05-10 2023-07-24 Solutex Na Llc Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
JP2018520197A (ja) * 2015-07-21 2018-07-26 アフィミューン リミテッド 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物
KR20180094516A (ko) 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법

Also Published As

Publication number Publication date
MX2015009803A (es) 2015-10-29
ZA201505018B (en) 2017-01-25
KR20220119524A (ko) 2022-08-29
KR20250105691A (ko) 2025-07-08
CN111214464A (zh) 2020-06-02
KR102434817B1 (ko) 2022-08-19
EP2762143A1 (en) 2014-08-06
US20210244697A1 (en) 2021-08-12
IL239893A (en) 2017-04-30
KR20240011872A (ko) 2024-01-26
US20210228524A1 (en) 2021-07-29
US20200069626A1 (en) 2020-03-05
IL239893A0 (en) 2015-08-31
ES2564025T3 (es) 2016-03-17
JP2016511753A (ja) 2016-04-21
CA2897343A1 (en) 2014-08-07
GB201301626D0 (en) 2013-03-13
SI2762143T1 (sl) 2016-04-29
RU2015136849A (ru) 2017-03-06
MX364646B (es) 2019-05-03
MX2019005082A (es) 2019-08-12
JP6363104B2 (ja) 2018-07-25
RS54584B1 (sr) 2016-08-31
CA2897343C (en) 2021-03-16
AU2018206685A1 (en) 2018-08-02
US10813903B2 (en) 2020-10-27
BR112015018270A2 (pt) 2017-07-18
EP2762143B1 (en) 2015-12-02
SMT201600069B (it) 2016-04-29
US20150224076A1 (en) 2015-08-13
KR20150112995A (ko) 2015-10-07
AU2014211628B2 (en) 2018-04-19
IL251639A0 (en) 2017-06-29
CY1117209T1 (el) 2017-04-05
SG10201806854XA (en) 2018-09-27
AU2014211628A1 (en) 2015-07-30
DK2762143T3 (en) 2016-03-07
EP3058943B1 (en) 2019-09-25
ZA201605125B (en) 2018-06-27
US20220347147A1 (en) 2022-11-03
HUE026901T2 (en) 2016-07-28
KR20210088733A (ko) 2021-07-14
WO2014118097A1 (en) 2014-08-07
KR102274963B1 (ko) 2021-07-08
PT2762143E (pt) 2016-03-28
ES2759448T3 (es) 2020-05-11
IL265876A (en) 2019-06-30
RU2671208C2 (ru) 2018-10-30
PH12015501582A1 (en) 2015-10-05
SG11201505457PA (en) 2015-08-28
CN105120872A (zh) 2015-12-02
US20250186384A1 (en) 2025-06-12
HK1200351A1 (en) 2015-08-07
EP3058943A1 (en) 2016-08-24
JP2018172409A (ja) 2018-11-08
HRP20160203T1 (hr) 2016-03-25
CN105120872B (zh) 2020-01-10
PH12015501582B1 (en) 2019-10-25
RU2018136872A (ru) 2018-11-27
NZ709803A (en) 2020-05-29
KR102514913B1 (ko) 2023-03-27
KR20230047201A (ko) 2023-04-06

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
IL265876A (en) Preparations that include 15-ohepa and methods of using them
GB2533892B (en) Compositions and methods
IL286759A (en) Therapeutic methods and preparations
SG11201509136YA (en) Cenicriviroc compositions and methods of making and using the same
GB201308072D0 (en) Compositions and methods
SMT201900635T1 (it) Composizioni e metodi di attivazione della segnalazione dipendente dallo "stimolatore di geni interferone"
GB201317286D0 (en) Composition and Use
ZA201509262B (en) Tuberculosis compositions and methods of using the same
PL3560558T3 (pl) Kompozycje nawozów oraz sposoby ich wytwarzania i stosowania
IL239840A0 (en) Polymyxins, preparations, methods of preparation and methods of use
GB201305813D0 (en) Compositions and methods
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
GB201322456D0 (en) Radiotracer compositions and methods
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same
GB201322617D0 (en) Methods and compositions
GB201312393D0 (en) Compositions and Methods
IL242818B (en) Il-1beta-il-1ra chimera and methods of using the same
GB201308242D0 (en) Compositions and uses thereof
GB201319255D0 (en) Therapeutic compositions and methods
GB201322467D0 (en) Composition and use
AU2013902874A0 (en) Compositions and methods